Correlation between high-risk TP53 mutation and extracapsular spread in oral squamous cell carcinoma

doi:10.19439/j.sjos.2019.06.018

Abstract

Abstract: PURPOSE: To investigate the correlation between high-risk tumor protein p53 (TP53) mutation and extracapsular spread(ECS) in oral squamous cell carcinoma (OSCC). METHODS: The data of 88 OSCC patients admitted to Gansu Provincial People's Hospital from January 2013 to January 2016 were retrospectively analyzed. The patients were divided into non-lymph node metastasis group (A₁), lymph node metastasis without ECS group (A₂), lymph node metastasis with ECS group(A₃) according to the presence or absence of lymph node metastasis. The deletion of exon 5-8 of TP53 gene in primary and metastatic lesions was detected. The correlation of ECS with disease-free survival(DFS), overall survival(OS) rate and TP53 mutation were determined, and single factor analysis of ECS was performed. The data were analyzed by SPSS 20.0 software package. RESULTS: TP53 (5) homozygote deletion was found in all three groups. TP53 (6) homozygous deletion was found in group A₃(10/30). No homozygous deletion of TP53(7) was found in three groups.Homozygous deletion of TP53 (8) was found in group A₂(7/42), group A₃(10/30) and group A₃(10/60).The 1-year and 3-year DFS rates were 75.00% and 70.83% in group A₁, 70.59% and 58.82% in group A₂, 46.67% and 40.00% in group A₃, with significant difference(P<0.05). The 1-year and 3-year OS rates were 83.33% and 75.00% in group A₁, 73.53% and 50.00% in group A₂, 46.67% and 40.00% in group A₃, with significant difference(P<0.05). In group A₃, there were 4 cases (13.33%) of low-risk TP53 mutation (LR), 12 cases (40.00%) of high-risk TP53 mutation (HR), 4 cases(13.33%) of wild-type TP53 mutation (Wt), and 10 cases(33.33%) of other mutations. HR mutation and other mutations occurred more frequently than other types(P<0.05). Smoking, primary lesion size, wild type/low risk and high risk/others were correlated with ECS(P<0.05). CONCLUSIONS: ECS is an important marker of DFS and OS in OSCC patients, and high-risk mutations were common in ECS, indicating a certain correlation between high-risk mutations of TP53 and ECS in OSCC.

Key words: TP53, OSCC, ECS, Gene mutation, Correlation

CLC Number:

R739.8

SHI Lei, TAO Feng, LIU Rui-min, LIU Qiao-rong. Correlation between high-risk TP53 mutation and extracapsular spread in oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2019, 28(6): 644-647.

References

[1] 张斌. 口腔鳞状细胞癌的表观遗传学研究现状和进展[J]. 口腔颌面外科杂志, 2016, 26(2): 77-82.
[2] Hema KN, Smitha T, Sheethal HS, et al.Epigenetics in oral squamous cell carcinoma[J]. J Oral Maxillofac Pathol, 2017, 21(2): 252-259.
[3] 袁芳, 金武龙. 舌癌临床治疗方法的选择及思考[J]. 世界最新医学信息文摘, 2016, 16(52): 63-64.
[4] 赵玉国, 张建文, 许瑞庭. 胃癌淋巴结包膜外侵犯与预后的关系研究[J]. 现代医药卫生, 2016, 32(5): 678-680.
[5] Suton P, Salaric I, Granic M, et al.Prognostic significance of extracapsular spread of lymph node metastasis from oral squamous cell carcinoma in the clinically negative neck[J]. Int J Oral Maxillofac Surg, 2017, 46(6): 669-675.
[6] 毕也, 周童, 张泽兵. 影响口腔鳞状细胞癌淋巴结转移及预后生物指标的相关研究进展[J]. 中国实验诊断学, 2017, 21(8): 1458-1461.
[7] 方勇, 蓝文贤, 孔令义. p53蛋白的结构生物学研究进展[J]. 生命的化学, 2016, 35(4): 467-474.
[8] Bouaoun L, Sonkin D, Ardin M, et al.TP53 Variations in human cancers: new lessons from the IARC TP53 database and genomics data[J]. Hum Mutat, 2016, 37(9): 856-876.
[9] 武现生, 唐云, 陈志达,等. VEGF和p53蛋白在甲状腺肿瘤中的表达及在诊断甲状腺良、恶性肿瘤中的应用价值研究[J]. 癌症进展, 2017, 15(4): 91-94.
[10] 陈晓文, 蒋宇杰, 曹玉文. 乳腺癌Kip1蛋白表达与患者无病生存率的相关性meta分析[J]. 中国保健营养, 2016, 26(24): 52.
[11] Huang Y, Liu Z, He L, et al.Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (Ⅰ or Ⅱ) non-small cell lung cancer[J]. Radiology, 2016, 281(3): 947-957.
[12] 刘怀, 李燕娴, 王勇,等. 肿瘤临床试验总生存时间的替代终点研究进展[J]. 肿瘤药学, 2017, 7(2): 129-134.
[13] Michiels S, Pugliano L, Marguet S, et al.Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer[J]. Ann Oncol, 2016, 27(6): 1029-1034.
[14] 朱宇星, 沈文怡. TP53基因与髓系肿瘤[J]. 国际输血及血液学杂志, 2017, 40(5): 408-412.
[15] Guedes L, Almutairi F, Haffner MC, et al.Analytic, pre-analytic and clinical validation of p53 immunohistochemistry for detection of TP53 missense mutation in prostate cancer[J]. Clin Cancer Res, 2017, 23(16): 4693-4703.